Zymeworks Inc. (ZYME) Buy Target – $45.75

Buy Target – $45.75
Sell Target – TradersPro Sell Signal

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company’s lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; and ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors.

 
Trending Ideas
  • 2 Stocks Driving Change in Food and HR Technology

    March 29, 2025

    The food service and human resources technology sectors are undergoing significant changes driven by shifting consumer preferences and rapid technological adoption. Kellanova (K) and Paychex, Inc. (PAYX) represent companies working... Read More

  • 2 Stocks Making Big Moves in Water and Power

    March 28, 2025

    The Utilities and Water Infrastructure sectors are undergoing significant changes driven by decarbonization mandates, rising energy demand, and growing concerns over water security. Southern Company (SO) and American Water Works... Read More

  • 3 Stocks Changing the Game in Food, Utilities, and Retail

    March 28, 2025

    The Food Production, Gas Utilities, and Grocery Retail sectors are each adapting to changing consumer behavior, supply chain dynamics, and energy market pressures. Pilgrim’s Pride Corporation (PPC), ONE Gas, Inc.... Read More



Featured Stocks On The Move